2022 Annual Meeting Virtual Experience | PL6 - Controversies in Neurology Plenary Session

Date Tuesday 04/26/22

Time 05:30 PM - 06:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Martinson K. Arnan, MD, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives This session features experts discussing the most current and controversial issues in neuroscience. Tune in for a scholarly debate between two expert speakers, each advocating for one side of a single topic, followed by a rebuttal.

CME Available 1.00 CME credit

Program Materials Program Evaluations

Event Timeline
05:30 PM - 05:35 PM EDT	Introduction	Introduction Martinson K. Arnan, MD, FAAN
05:35 PM - 05:47 PM EDT	Speaker	Yes: Should Anticoagulation be Restarted After Cerebral Hemorrhage for Secondary Stroke Prevention in AFib? Kevin N. Sheth, MD, FAAN
05:47 PM - 05:59 PM EDT	Speaker	No: Should Anticoagulation be Restarted After Cerebral Hemorrhage for Secondary Stroke Prevention in AFib? Edip M. Gurol, MD
05:59 PM - 06:04 PM EDT	Speaker	Rebuttal: Should Anticoagulation be Restarted After Cerebral Hemorrhage for Secondary Stroke Prevention in AFib? Kevin N. Sheth, MD, FAAN
06:04 PM - 06:09 PM EDT	Speaker	Rebuttal: Should Anticoagulation be Restarted After Cerebral Hemorrhage for Secondary Stroke Prevention in AFib? Edip M. Gurol, MD
06:09 PM - 06:30 PM EDT	Q&A	Fireside Chat Martinson K. Arnan, MD, FAAN, Edip M. Gurol, MD, Kevin N. Sheth, MD, FAAN

Faculty Disclosures
Martinson K. Arnan, MD, FAAN	Dr. Arnan has nothing to disclose.
Edip M. Gurol, MD	The institution of Dr. Gurol has received research support from NIH/NINDS. The institution of Dr. Gurol has received research support from Boston Scientific Corporation. The institution of Dr. Gurol has received research support from AVID (a wholly owned subsidiary of Eli Lilly). The institution of Dr. Gurol has received research support from Pfizer.
Kevin N. Sheth, MD, FAAN	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.